|
Fareston
(generic name, toremifene)
Similar to tamoxifen, Fareston (generic name, toremifene) is an anti-estrogen (SERM, selective estrogen-receptor
modulator). Fareston binds to estrogen receptors on breast cancer cells, preventing the cells from growing
and dividing. Advanced breast cancer patients are usually prescribed one 60-milligram tablet of Fareston daily.
Possible side effects include:
- Hot flashes
- Nausea
- Weight gain
- Allergic reactions (such as skin rashes)
- Headache
Click here for additional information on Fareston (courtesy of GTx, Inc.).
Femara
(generic name, letrozole)
Femara (generic name, letrozole) was approved by the U.S. Food and Drug Administration
(FDA) in 1997 to help treat advanced (metastatic) breast cancer in women whose breast cancer tumors have not
responded well to tamoxifen. Femara works by reducing the total amount of estrogen in the body (circulating
estrogen levels), thereby limiting the amount of estrogen that can affect breast cancer cells. In post-menopausal
women, the body produces estrogen from other hormones known as androgens by the action of an enzyme called
aromatase. Femara is an aromatase inhibitor and blocks aromatase from converting androgen into estrogen, thus
lowering the amount of estrogen in the body. Researchers are investigating whether Femara should be considered
as a first option ("first-line therapy") in treating some women with advanced breast cancer.
Possible side effects of Femara may include:
- Musculoskeletal pain (pain in the skeleton or legs, arms or back)
- Nausea
- Headache
- Joint pain
- Fatigue
- Difficulty breathing
A 2007 study found that some breast cancer patients that take Aromasin (ore Femara) experience side effects such as
joint and muscle pain and more than 10% of the patients in the study stopped treatement due to these effects. The
researchers are investigating alternative treatments or methods to managing side effects in such patients. They
suggest that tamoxifen may be a better choice for treatment of women who experience these side
effects. Click here for more information.
Click here for additional information and full prescribing information
on Femara (courtesy of Novartis Oncology).
Herceptin
(generic name, trastuzumab)
Herceptin
(generic name, trastuzumab) is FDA approved to treat advanced
(metastatic) breast cancer in women who over-express the HER2 gene. HER2 (also written
HER-2/neu) is a growth factor found on the surface of cells that plays a key role in
regulating cell growth. Some women are born with or experience a mutation of the HER2 gene
throughout their lifetime. When altered, extra HER2 receptors may be produced. This
over-expression of HER2 causes cells to grow, divide, and multiply more rapidly than
normal and may lead to breast cancer. Women who over-express the HER2 gene tend to have
aggressive breast cancers that spread quickly to other regions of the body.
Herceptin seeks out HER2 and attaches
itself to the protein receptor on the surface of cells. By binding to the cells, Herceptin
has been shown to slow the growth and spread of tumors that have an overabundance of HER2
protein receptors. Herceptin is usually given intravenously (through the vein) in an
outpatient clinical setting.
Possible side effects of Herceptin
include:
- Weakening of the heart muscle
- Reduction of white blood cells
(leukopenia or neutropenia)
- Diarrhea
- Anemia (a decreased number of red blood
cells and a reduced volume of hemoglobin: the protein within red blood cells that carries
oxygen)
- Abdominal pain or infection
Click here for additional information and full prescribing information on
herceptin (courtesy of Genentech).
Megace
(generic name, megestrol)
Megace (generic name, megestrol) is used to treat advanced breast cancer, typically in women who do
not respond well or become resistant to tamoxifen. Megace is a synthetic form of the hormone,
progesterone. Progesterone is normally secreted by the corpus luteum of the ovary and by the placenta
and acts to prepare the uterus for implantation of the fertilized ovum, to maintain pregnancy, and to
promote development of secondary sexual characteristics. Progesterone also counteracts some of the negative
effects of estrogen (many breast cancers depend on estrogen to grow and reproduce).
In addition to treating advanced breast cancer, Megace may also be used to treat advanced stages of
endometrial cancer (cancer of the uterine lining) or to increase appetite in HIV patients. Because
Megace is considered non-toxic, there are few documented side effects associated with the drug. The
most common side effect is fluid retention.
Click here for additional information and full prescribing information on Megace (courtesy of Bristol Myers
Squibb; requires Adobe Acrobat).
Resources:
Bristol-Myers Squibb, the maker of Megace (megestrol) provides additional information and full prescribing
information on Megace at http://www.bms.com/
Tamoxifen
Tamoxifen
has been the most commonly prescribed drug to treat breast cancer
since its approval by the U.S. Food and Drug Administration (FDA) in the 1970s. Tamoxifen
is an anti-estrogen and works by competing with the hormone estrogen to bind to estrogen
receptors in breast cancer cells. By blocking estrogen in the breast, tamoxifen helps slow
the growth and reproduction of breast cancer cells. In 1998, tamoxifen became the first
drug to be approved by the FDA to prevent breast cancer after research showed it reduced
the chances of developing breast cancer by 50% in women at high
risk for the disease. Tamoxifen is taken orally in pill form.
Possible side effects of tamoxifen include:
- Hot flashes
- Irregular menstrual cycles
- Unusual vaginal discharge or bleeding
- Irritation of skin around vagina
Click here for additional information on
tamoxifen (courtesy of the National Cancer Institute).
CONTINUED
< Prev | 1 | 2 | 3 | 4 | Next >
Return to Treatment Main Menu |